Log in

NASDAQ:ABEOAbeona Therapeutics Stock Price, Forecast & News

$2.75
-0.08 (-2.83 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.71
Now: $2.75
$2.83
50-Day Range
$2.77
MA: $2.94
$3.42
52-Week Range
$1.35
Now: $2.75
$5.19
Volume739,519 shs
Average Volume1.29 million shs
Market Capitalization$233.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Read More
Abeona Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABEO
Previous SymbolOTCMKTS:ACCP
CUSIPN/A
Phone214-665-9495

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$2.13 per share

Profitability

Net Income$-76,280,000.00

Miscellaneous

EmployeesN/A
Market Cap$233.14 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$2.75
-0.08 (-2.83 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

How has Abeona Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Abeona Therapeutics' stock was trading at $2.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABEO shares have increased by 25.6% and is now trading at $2.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Abeona Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Abeona Therapeutics
.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Abeona Therapeutics
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.03.
View Abeona Therapeutics' earnings history
.

What price target have analysts set for ABEO?

5 brokers have issued twelve-month price objectives for Abeona Therapeutics' stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Abeona Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 136.4% from the stock's current price.
View analysts' price targets for Abeona Therapeutics
.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:
  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (7/8/2020)
  • 2. Mizuho analysts commented, "We remain on the sidelines until we can gain more confidence in the company’s execution. Reiterate Neutral / $4 PT." (9/23/2019)

Has Abeona Therapeutics been receiving favorable news coverage?

News headlines about ABEO stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abeona Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Abeona Therapeutics
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,850,000 shares, an increase of 31.3% from the May 31st total of 2,170,000 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 2.6 days.
View Abeona Therapeutics' Short Interest
.

Who are some of Abeona Therapeutics' key competitors?

What other stocks do shareholders of Abeona Therapeutics own?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the following people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (1.30%), Rhenman & Partners Asset Management AB (1.11%), Hudson Bay Capital Management LP (0.57%), Bank of New York Mellon Corp (0.32%), Goldman Sachs Group Inc. (0.27%) and California Public Employees Retirement System (0.16%). Company insiders that own Abeona Therapeutics stock include Stefano Buono and Stephen B Howell.
View institutional ownership trends for Abeona Therapeutics
.

Which institutional investors are selling Abeona Therapeutics stock?

ABEO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Rhenman & Partners Asset Management AB, WS Management Lllp, Assenagon Asset Management S.A., and UBS Group AG.
View insider buying and selling activity for Abeona Therapeutics
.

Which institutional investors are buying Abeona Therapeutics stock?

ABEO stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, California Public Employees Retirement System, SG Americas Securities LLC, New York State Common Retirement Fund, Meitav Dash Investments Ltd., Bank of New York Mellon Corp, State Board of Administration of Florida Retirement System, and Prudential Financial Inc.. Company insiders that have bought Abeona Therapeutics stock in the last two years include Stefano Buono, and Stephen B Howell.
View insider buying and selling activity for Abeona Therapeutics
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $2.75.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $233.14 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-76,280,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

What is Abeona Therapeutics' official website?

The official website for Abeona Therapeutics is www.abeonatherapeutics.com.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.